Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine
about
sameAs
Development and application of a positive-negative selectable marker system for use in reverse genetics in Plasmodium.Cytomegalovirus antivirals and development of improved animal modelsA new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoIn vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infectionsNucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient miceCharacterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells.Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis.New antiherpes drugs in development
P2860
Q25257810-ECD7DBAF-2509-4A87-A7BC-39A11AF877E2Q27000998-D833B05C-BCE4-4F66-9252-ED1B5F8A0A76Q27490484-C696B3C9-ADC9-4756-8054-9B5FE5D934FAQ28344285-74125F22-3D2F-46B7-9435-FFECB2C1167DQ33759331-41C8B1F1-3D9E-4758-9B98-05805C91FAD0Q34107597-B90DAF7D-E495-4AD1-A72F-E1D4DF37AE3AQ35126399-D04D15AD-9EAA-420F-AC20-96EE38D38E92Q35558801-17B4949E-6A71-4DCA-8B3D-BB1E9032419BQ35892584-EBD1F104-CCFE-40E0-B7F5-813DBB58991BQ37624896-A3E4879B-F388-4351-8A17-DFBE62C2A4A7Q37734561-8A0A40F9-25A3-4C45-B8C6-D5B3F4D47FA7Q39781466-DD24B632-6B42-48AE-836C-72D93D206951Q47192748-68F1A1AB-E936-479B-86F9-471CE6414A8FQ56864665-701B563A-2CEE-418D-A44B-AEA1484F499F
P2860
Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@ast
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@en
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@nl
type
label
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@ast
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@en
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@nl
prefLabel
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@ast
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@en
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@nl
P2093
P2860
P356
P1476
Treatment of murine cytomegalo ...... e, interferon, and bropirimine
@en
P2093
P2860
P304
P356
10.1128/AAC.36.9.1837
P407
P50
P577
1992-09-01T00:00:00Z